BLOG

opthalmology times

Ashvattha Therapeutics enrolls first patient in Phase 2 study of D-4517.2 for treatment of wet AMD, DME

Ashvattha Therapeutics today announced that the first patient has been enrolled in a two-stage Phase 2 clinical study of D-4517.2, an HDT with potent anti-VEGF activity.